within Pharmacolibrary.Drugs.ATC.V;

model V09IX05
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.4999999999999998e-06,
    adminDuration  = 600,
    adminMass      = 185 / 1000000,
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.002,
    k12             = 1.6666666666666667e-06,
    k21             = 1.6666666666666667e-06
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Fluorodopa18f</td></tr><tr><td>ATC code:</td><td>V09IX05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fluorodopa (18F), also known as 6-[18F]fluoro-L-dopa, is a radiolabeled analog of the amino acid L-dopa used primarily as a diagnostic imaging agent in positron emission tomography (PET) for the assessment of presynaptic dopaminergic function, especially in the diagnosis and evaluation of Parkinsonâ€™s disease and related movement disorders. It is not used as a therapeutic drug, but as a diagnostic tool approved in several countries for PET imaging.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers and patients undergoing PET imaging studies.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>"
  ));
end V09IX05;
